Kinase Inhibitor Profile For Human Nek1, Nek6, And Nek7 And Analysis Of The Structural Basis For Inhibitor Specificity. by Moraes, Eduardo Cruz et al.
Molecules 2015, 20, 1176-1191; doi:10.3390/molecules20011176 
 
molecules 
ISSN 1420-3049 
www.mdpi.com/journal/molecules 
Article 
Kinase Inhibitor Profile for Human Nek1, Nek6, and Nek7 and 
Analysis of the Structural Basis for Inhibitor Specificity 
Eduardo Cruz Moraes 1,2,†, Gabriela Vaz Meirelles 1,2,†, Rodrigo Vargas Honorato 1,  
Tatiana de Arruda Campos Brasil de Souza 3, Edmarcia Elisa de Souza 1,2,  
Mario Tyago Murakami 1, Paulo Sergio Lopes de Oliveira 1 and Jörg Kobarg 2,4,5,* 
1 LaboratórioNacional de Biociências, Centro Nacional de PesquisaemEnergia e Materiais, 
Campinas, 13083-970 SP, Brazil; E-Mails: eduardo.moraes@bioetanol.org.br (E.C.M.); 
gabriela.meirelles@lnbio.cnpem.br (G.V.M.); rodrigo.honorato@lnbio.cnpem.br (R.V.H.); 
edmarcia.souza@lnbio.cnpem.br (E.E.S.); mario.murakami@lnbio.cnpem.br (M.T.M.);  
paulo.oliveira@lnbio.cnpem.br (P.S.L.O.) 
2 Programa de Pós-graduação em Biologia Funcional e Molecular, Departamento de Bioquímica e 
BiologiaTecidual, Instituto de Biologia, UniversidadeEstadual de Campinas, Campinas,  
13083-862 SP, Brazil 
3 Instituto Carlos Chagas, FIOCRUZ, Curitiba, 81350-010 PR, Brazil;  
E-Mail: tatiana.brasil@gmail.com  
4 Departamento de Bioquímica e de Biologia Tecidual, Instituto de Biologia,  
Universidade Estadual de Campinas, Campinas, 13083-862 SP, Brazil 
5 Faculdade de Ciências Farmacêuticas, Universidade Estadual de Campinas, Campinas,  
13083-859 SP, Brazil 
† These authors contributed equally to this work. 
* Author to whom correspondence should be addressed; E-Mail: jorgkoba@unicamp.br;  
Tel.: +55-19-3521-1443. 
Academic Editor: Jean Jacques Vanden Eynde 
Received: 4 November 2014 / Accepted: 5 January 2015 / Published: 13 January 2015 
 
Abstract: Human Neks are a conserved protein kinase family related to cell cycle 
progression and cell division and are considered potential drug targets for the treatment of 
cancer and other pathologies. We screened the activation loop mutant kinases hNek1 and 
hNek2, wild-type hNek7, and five hNek6 variants in different activation/phosphorylation 
statesand compared them against 85 compounds using thermal shift denaturation.  
We identified three compounds with significant Tm shifts: JNK Inhibitor II for  
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hNek1(Δ262-1258)-(T162A), Isogranulatimide for hNek6(S206A), andGSK-3 Inhibitor 
XIII for hNek7wt. Each one of these compounds was also validated by reducing the 
kinases activity by at least 25%. The binding sites for these compounds were identified by 
in silico docking at the ATP-binding site of the respective hNeks. Potential inhibitors were 
first screened by thermal shift assays, had their efficiency tested by a kinase assay, and 
were finally analyzed by molecular docking. Our findings corroborate the idea of  
ATP-competitive inhibition for hNek1 and hNek6 and suggest a novel non-competitive 
inhibition for hNek7 in regard to GSK-3 Inhibitor XIII. Our results demonstrate that our 
approach is useful for finding promising general and specific hNekscandidate inhibitors, 
which may also function as scaffolds to design more potent and selective inhibitors. 
Keywords: drug discovery; compound screening; kinase assays; molecular modeling; 
molecular docking; ATP-competitive inhibitors; non-competitive inhibition; Neks 
 
1. Introduction 
Protein kinases (PKs) play an important role in the activation of biochemical pathways in 
eukaryotic cells. With over 500 described kinases encoded in the human genome, virtually every signal 
transduction process is wired through a phosphotransfer cascade. Therefore, the tight regulation of 
phosphorylation is crucial for cell growth and development, and this regulation relies on the proper 
regulation of kinase proteins. Protein kinase domains are found in ~2% of eukaryotic genes [1], which 
also reflects their importance. These proteins typically share a conserved arrangement of secondary 
structure elements into 12 subdomains that fold into a bi-lobed catalytic core structure with ATP 
binding in a deep cleft located between the lobes [2], and their homologous catalytic domain consists 
of ~250–300 amino acid residues [3]. PKs catalyze the transfer of the γ-phosphate of ATP to the 
hydroxyl group of serine, threonine or tyrosine of the substrate protein and are considered “molecular 
switches”, since they can adopt an “on” state [4–7]. 
NIMA-related kinases (Neks) are a conserved serine/threonine PK family related to cell cycle 
progression and cell division. These proteins share about 40% identity in the N-terminal catalytic 
domain to the NIMA (never in mitosis, gene A) protein of Aspergillus nidulans, which performs 
mitotic roles similar to the mammalian Neks [8,9]. Among these, Nek2 is the best studied, being 
described as a protein located in the centrosomes and kinetochores [10] that regulates the centrosome 
separation in the G2/M transition, thus being fundamental for the mitotic spindle formation [11]. Nek6 
and Nek7 are the smallest proteins of the Nek family. Most of their structure is constituted of the catalytic 
domain, which is located in the C-terminal region [12]. Endogenous Nek6 is activated during mitosis 
and has its expression level increased during this process [13]. Overexpression of inactivated mutants 
of Nek6 and Nek7 shows similar phenotypes, with cells displaying high division rates, defects in the 
mitotic spindle, abnormal nuclei, and apoptosis [14,15]. These phenotypes are also observed by the 
iRNA silencing of Nek6 and Nek7 in Hela cells, leading to a cell cycle arrest in metaphase, with cells 
showing normal chromosome condensation but a disability to segregate them. Therefore, Nek6 and 
Nek7 play a crucial role in cell cycle progression to the anaphase [14–16]. Nek9 is also described to 
Molecules 2015, 20 1178 
 
 
interact with Nek6 and Nek7, where the latter are activated by the phosphorylation of the former, 
which is activated during mitosis [13,17]. 
Moreover, several Neks are products of genes related to pathologies, such as diseases associated 
with defects in cell cycle progression and DNA repair mechanisms during interphase, especially 
carcinomas [9]. Mutation in Nek1 and Nek8 genes are related to polycystic kidney disease [18,19], 
Nek6 overexpression is observed in hepatocellular carcinomas [20], and studies also show that Nek6 
and Nek1 are related to DNA damage checkpoints [21,22]. 
Due to these characteristics, Neks have emerged as potential targets for treatment of cancers and 
development of anti-cancer drugs. Hence, there is a great interest in the identification of potential 
inhibitors for these kinases. Some of these inhibitors were experimentally proposed for human  
Nek2 [23–25], others were only evaluated by in silico techniques for hNek6 [26], though for the  
majority of Neks these studies remain elusive, in part due to the lack of a crystal structure, which  
isnow available only for hNek2 [27,28], hNek7 [29], and hNek1. In this context, a number of recent 
successful drugs have emerged from a structure-based research approach [30], and most of the efforts  
to develop low molecular-weight inhibitors that have entered clinical programs are focused on  
ATP-competitive compounds. 
Here we present the evaluation of the efficiency of an ATP-competitive compounds library by the 
use of three procedures: thermal shift assays, kinase activity assays and molecular docking. Thermal 
shift assays allow quantifying the stability of the protein-ligand interaction by the protein unfolding in 
an increasing temperature range [31]. Kinase activity assays evaluate the increase or decrease of 
enzyme activity in the presence of ligands by the phosphorylation rate of a certain substrate. Molecular 
docking provides in silico evaluation of the protein-ligand interaction region and affinity calculated 
using a scoring function based on an approximate force field [32]. Thereby, potential inhibitors were 
first screened by thermal shift assays, had their efficiency tested by a kinase inhibition assay and had 
their conformation and placement predicted by molecular docking. 
2. Results and Discussion 
2.1. Screening of ATP-Competitive Inhibitors for Recombinant Human Neks 1, 2, 6, and 7 by Thermal 
Shift Assay 
Aiming to find possible inhibitors for hNeks 1, 6 and 7 in a drug design approach, we performed a 
screen using Inhibitor Select™ 96-Well Protein Kinase Inhibitor Library II (Calbiochem), containing 
80 inhibitors targeting mostly Ser/Thr kinases, and five other compounds (AMP, ADP, ATP, ATP-g-S, 
and SU11652) (Supplementary File). In a previous work using the thermal stability shift assay, 156 
validated kinase inhibitors were screened against 60 human Ser/Thr kinases, including recombinant 
hNek2 and hNek6, but no significant Tm shift (ΔTm> 4.0 °C) was detected for hNek6 [33]. Here we 
screened 85 compounds against recombinant hNek1(Δ262-1258)-(T162A), hNek7wt and five recombinant 
hNek6 variants—6xHis-hNek6wt, 6xHis-hNek6(S206A), 6xHis-hNek6(Δ1-44), 6xHis-hNek6wtD and 
6xHis-hNek6(S206A)D—and used hNek2(Δ272-445)-(T175A) as a control, since it had already been 
used in the previous screen by Fedorov et al. [33], in order to search for potential inhibitors. We were 
also interested in observing whether the hNek6 activation/phosphorylation status might interfere with 
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its stability in the presence of different compounds and whether this characteristic could influence the 
search and/or development of novel inhibitors for this kinase. In this context, thermal shift assays for 
the five recombinant hNek6 variants were described to reveal a slightly higher stability for wild-type 
hNek6 compared to the activation loop mutant [12]. 
From this screen, we were able to retrieve one compound with significant Tm shift for  
hNek1(Δ262-1258)-(T162A), JNK Inhibitor II, and one for hNek6(S206A), Isogranulatimide  
(Table 1). On the other hand, hNek7wt and our control, hNek2(Δ272-445)-(T175A), retrieved 10 and  
5 hit compounds, respectively, with significant Tm shifts: Cdk1/2 Inhibitor III, GSK-3 Inhibitor XIII, 
PD 169316, JNK Inhibitor V, MK2a Inhibitor, Indirubin-3'-monoxime, Isogranulatimide, K-252a, 
Indirubin Derivative E804and SB 218078for hNek7wt; and Aminopurvalanol A, NF-kB Activation 
Inhibitor, JNK Inhibitor II, K-252a and SU11652 for hNek2(Δ272-445)-(T175A) (Table 1). The 
compound SU11652, retrieved here for hNek2(Δ272-445)-(T175A), had also been identified for this 
kinase with a significant Tm shift (ΔTm = 5.1 °C) in the previous screen by Fedorov et al. [33], 
contributing to validate our assays. 
Table 1. Summary of recombinant hNeks 1, 2, 6 and 7 thermal shift inhibitor screen 
showing only compounds withΔTm ≥ 2 °C. Names of compounds showing a significant 
thermal shift (ΔTm ≥ 4 °C) are depicted in bold. 
Nek CAS Number Compound Description ΔTm (°C) 
Nek1(Δ262-1258)-(T162A) 667463-62-9 GSK-3 Inhibitor IX 3.5 
Nek1(Δ262-1258)-(T162A) 444723-13-1 Cdk2 Inhibitor IV, NU6140 3.1 
Nek1(Δ262-1258)-(T162A) 879127-16-9 Aurora Kinase Inhibitor III 3.6 
Nek1(Δ262-1258)-(T162A) 443798-55-8 Cdk1/2 Inhibitor III 2.6 
Nek1(Δ262-1258)-(T162A) 220792-57-4 Aminopurvalanol A 2.5 
Nek1(Δ262-1258)-(T162A) 4129-56-6 JNK Inhibitor II 4.0 
Nek2(Δ272-445)-(T175A) 220792-57-4 Aminopurvalanol A 4.0 
Nek2(Δ272-445)-(T175A) 866405-64-3 AMPK Inhibitor, Compound C 2.5 
Nek2(Δ272-445)-(T175A) 326914-10-7 SU11652 9.6 
Nek2(Δ272-445)-(T175A) 4129-56-6 JNK Inhibitor II 4.8 
Nek2(Δ272-445)-(T175A) 97161-97-2 K-252a, Nocardiopsis sp. 5.4 
Nek2(Δ272-445)-(T175A) 522629-08-9 MNK1 Inhibitor 2.1 
Nek2(Δ272-445)-(T175A) 545380-34-5 NF-kB Activation Inhibitor 4.2 
Nek2(Δ272-445)-(T175A) 601514-19-6 GSK3b Inhibitor XII, TWS119 2.3 
Nek6(S206A) 62996-74-1 Staurosporine, Streptomyces sp. 2.1 
Nek6(S206A) 852527-97-0 Alsterpaullone, 2-Cyanoethyl 2.5 
Nek6(S206A) 244148-46-7 Isogranulatimide 6.5 
Nek7wt 345987-15-7 JNK Inhibitor V 4.9 
Nek7wt 443798-55-8 Cdk1/2 Inhibitor III 4.2 
Nek7wt 135897-06-2 SB 218078 11.5 
Nek7wt 152121-53-4 PD 169316 4.4 
Nek7wt 62996-74-1 Staurosporine, Streptomyces sp. 3.2 
Nek7wt 97161-97-2 K-252a, Nocardiopsis sp. 8.8 
Nek7wt 244148-46-7 Isogranulatimide 8.3 
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Table 1. Cont. 
Nek CAS Number Compound Description ΔTm (°C) 
Nek7wt 404828-08-6 GSK-3 Inhibitor XIII 4.3 
Nek7wt 220792-57-4 Aminopurvalanol A 3.0 
Nek7wt 41179-33-3 MK2a Inhibitor 5.3 
Nek7wt 854171-35-0 Indirubin Derivative E804 9.7 
Nek7wt 160807-49-8 Indirubin-3'-monoxime 7.9 
Nek7wt 487021-52-3 GSK-3b Inhibitor VIII 3.3 
Nek7wt 4129-56-6 JNK Inhibitor II 2.6 
Our results also show that one compound, Isogranulatimide, produced a significant Tm shift for 
hNek6(S206A), but not for the other variants (Table 2). Moreover, the activation loop mutant, 
dephosphorylated or not, showed a higher number of cases in which a compound produced a Tm shift 
of at least 2 °C—three cases for hNek6(S206A) and ten cases for hNek6(S206A)D—compared to the  
wild-type hNek6—no cases for hNek6wt, hNek6wtD or 6xHis-hNek6(Δ1-44) (Table 2). These data 
together suggest that a partially activated hNek6 kinase, without being phosphorylated at its activation 
loop, is a better target for inhibitor stabilization than an activated more phosphorylated kinase. 
Table 2. Summary of hNek6 variants thermal shift inhibitor screen. A thermal shift of at 
least 2 °C (ΔTm ≥ 2 °C) is depicted in italics and a significant thermal shift (ΔTm > 4 °C) is 
depicted in bold. (D: dephosphorylated). 
CompoundDescription Nek6wt Nek6wtD Nek6(S206A) Nek6(S206A)D Nek6(Δ1-44) 
Alsterpaullone 0.0 0.1 1.4 2.9 −0.5 
Alsterpaullone, 2-Cyanoethyl 0.0 −0.1 2.5 2.5 −0.2 
Aminopurvalanol A 0.3 −1.8 0.8 _ −0.2 
Aminopyrazole1 −0.4 0.1 1.0 2.4 0.0 
AR-A014418 0.3 −0.5 1.4 2.6 −0.2 
Indolinone1 _ −0.4 −0.2 2.1 −0.5 
Indolocarbazole1 −0.3 −0.1 1.7 0.7 −1.3 
Isogranulatimide 1.2 0.6 6.5 2.3 −0.7 
JNJ-7706621 0.0 0.6 0.7 2.1 −0.7 
Pyrazolanthrone 0.3 −1.1 1.8 2.3 0.1 
Staurosporine 0.3 −0.7 2.1 2.3 _ 
TPCA-1 0.0 −0.7 0.9 2.0 −1.7 
In this context, the Isogranulatimide compound was identified as a G2 DNA damage checkpoint 
inhibitor containing a unique indole/maleimide/imidazole skeleton in a phenotypic cell-based  
screen [34], and in vitro kinase assays showed that it inhibits Chk1 (IC50 = 0.1 μM) and GSK-3 beta  
(IC50 = 0.5 µM) [35]. Human Nek6 hasrecently been described to be phosphorylated upon exposure to 
Ionizing radiation or UV irradiation through the DNA damage checkpoint in vivo, probably by the 
checkpoint kinases Chk1 and Chk2, which is suggested to be required for proper cell cycle arrest in the 
G2/M phase upon DNA damage [22]. Therefore, since hNek6 is involved in the G2/M phase cell cycle 
arrest through DNA damage-induced phosphorylation and is also a target of Isogranulatimide, besides 
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Chk1 itself, hNek6 may be a promising candidate for modulating checkpoint responses in tumors for 
therapeutic benefit. 
2.2. Kinase Assays of Selected Candidate Compounds for Recombinant Human Neks 1, 6, and 7 
In order to confirm whether the retrieved compounds from the thermal shift assays could also 
inhibit the kinases activities, in vitro kinase assays were performed. As expected, JNK Inhibitor II 
compound retrieved in our screen for hNek1(Δ262-1258)-(T162A) with a significant Tm shift  
(ΔTm = 4.0 °C) was able to reduce its activity in almost 30% (to 71.5% ± 0.1%) at a 50 µM 
concentration (Table 3). As also expected for hNek6(S206A), the Isogranulatimide compound showing 
a significant Tm shift (ΔTm = 6.5 °C) was able to reduce its activity to 74.9% ± 10.4% at 0.625 μM. 
Moreover, regarding hNek7wt, one compound, GSK-3 Inhibitor XIII, with a significant Tm shift  
(ΔTm = 4.3 °C) reduced hNek7 activity to 46.3% ± 2.9% (1.25 µM) and 43.3% ± 10.1% (0.312 µM). 
Although not showing Tm shifts above 4.0 °C, two other compounds were also effective in reducing 
hNek7 activity: Aminopurvalanol A (ΔTm = 3.0 °C) and GSK-3b Inhibitor VIII (ΔTm = 3.3 °C). 
Aminopurvalanol A reduced hNek7 activity up to 35.9% ± 3.3% (0.625 µM), while GSK-3b Inhibitor 
VIII reduced it up to 44.3% ± 3.3% (0.312 µM) (Table 3). 
2.3. Molecular Docking of Selected Inhibitors for Recombinant Human Neks 1, 6, and 7 
Selected candidate inhibitors (Table 3) were subjected to global docking analysis and had their 
energy and conformation analyzed. The ATP-binding site was identified on each target-ligand complex 
based on the molecular models of hNek1(Δ262-1258)-(T162A) and hNek6(S206A) and on the crystal 
structure of hNek7 (PDB: 2WQN) [29]. All docking conformations were ranked based on their energy 
values, and it was observed that the top hit conformations (lowest binding energy) of each complex 
were located in the ATP-binding site (Figure 1A–C). Total predicted ligand-protein binding energies 
are depicted in Table 3. 
The ATP-binding site in hNeks is characterized by a pocket predominantly positively charged 
responsible for anchoring the polar tail of ATP. This site is very conserved among Neks, and in our 
reference hNek2 (PDB: 2W5A) it is structurally constituted by the following residues: I14, G15, T16, 
G17, S18, Y19, G20, R21, C22, V35, K37, V68, M86, E87, Y88, C89, E90, G92, D93, S96, K143, A145, N146, F148, 
D159, F160, and R164. The ATP-binding region signature considering only the primary sequence analysis 
in ScanProsite [36] for all 11 human Neks consists of about 23 amino acid residues between I14 and 
K37 (hNek2 numbering) [12]. Interestingly, 10 interactions (about 40%) in hNeks 1,6 and 7 bound to 
their respective candidate compounds in a corresponding way as  the interactions that occurr in the 
ATP-binding pocket of hNek2 (PDB: 2W5A) with ADP (Figure 1A’–C’). 
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Table 3. Summary of compounds with thermal shifts of at least 3 °C (ΔTm ≥ 3 °C), total predicted ligand-protein binding energies in  
ATP-binding site and percent phosphorylation activity up to 75% for recombinant hNeks 1, 6, and 7. The percent phosphorylation is 
according to a compound final concentration of 2×, 1×, and 0.5× the ATP Km[apparent] concentration of each kinase. The ATP Km[apparent] 
concentrations found for Neks are as follows: 0.625 µM for hNek6(S206A) and hNek7wt, and 25 µM for hNek1(Δ262-1258)-(T162A). Only 
percentage of phosphorylation values with standard errors < 20 are depicted in the table. Names of compounds corresponding to ΔTm ≥ 4.0 °C 
and phosphorylation ≤ 75% are depicted in bold and were selected as the best candidates for hNeks. 
Nek 
CAS 
Number 
Compound 
Description 
ΔTm (°C) Docked/Predicted Binding 
Energy (kcal/mol) 
Phosphorylation 
(%) 2× b 
Phosphorylation 
(%) 1× b 
Phosphorylation 
(%) 0.5× b 
Nek1(Δ262-1258)-(T162A) 4129-56-6 JNK Inhibitor II 4.0 −7.345 71.5 ± 0.1 87.3 ± 18.3 - 
Nek6(S206A) 244148-46-7 Isogranulatimide a 6.5 −8.917 - 74.9 ± 10.4 100.2 ± 1.3 
Nek7wt 220792-57-4 Aminopurvalanol A 3.0 −8.626 41.0 ± 13.5 35.9 ± 3.3 64.4 ± 3.4 
Nek7wt 487021-52-3 GSK-3b Inhibitor VIII 3.3 −7.572 58.1 ± 3.2 47.5 ± 4.4 44.3 ± 3.3 
Nek7wt 404828-08-6 GSK-3 Inhibitor XIII 4.3 −8.629 46.3 ± 2.9 - 43.3 ± 10.1 
a: Isogranulatimide was selected for hNek6(S206A), although corresponding to a minimum percentage of phosphorylation of 74.9 ± 10.4; b: S.E. of two measurements. 
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Figure 1. Representationofbestcandidate compounds complexed to recombinant hNeks 1, 
6, and 7 in comparison withhNek2 in the ATP-binding site. (A–C) Three-dimensional 
representation of the top docking position for each compound-target complex in the  
ATP-binding site (red). (A’–C’) Three-dimensional representation of the interactions between 
each target protein (cyan) and candidate compound (magenta) in comparison to our 
reference hNek2 (PDB: 2W5A) (orange) boundto ADP (green). Amino acid residue labels 
are depicted in orange for the reference hNek2 and in black for the other hNeks. (A”–C”) 
Three-dimensional representation of the preferable area occupied by candidate compounds 
(magenta) relative to ADP (green) in the ATP-binding site cavity (grey) of our reference 
hNek2 (PDB: 2W5A) identified by KV Finder. The binding subsites are depicted as 
follows: (1) adenine region; (2) ribose region; and (3) phosphate groups region.  
(A) hNek1(Δ262-1258)-(T162A) bound to JNK Inhibitor II; (B) hNek6(S206A) bound to 
Isogranulatimide; (C) hNek7wt bound to GSK-3 Inhibitor XIII. 
Moreover, the same cavity occupied by ADP in the crystal structure of hNek2 (PDB: 2W5A) could 
also be occupied by the candidate compounds identified for hNek1(Δ262-1258)-(T162A), hNek6(S206A) 
and hNek7wt, where JNK Inhibitor II preferentially occupies the adenine region, Isogranulatimide 
extends to the ribose region, and GSK-3 Inhibitor XIII occupies the phosphate groups region and  
A A’ 
B B’ 
C C’ 
A” 
B” 
C” 
1 
2 
3 
1 
2 
3 
2 
1 
3 
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beyond (Figure 1A”–C”). Surprisingly, from the three candidate compounds, two behave as expected  
ATP-competitive inhibitors, but one, GSK-3 Inhibitor XIII, is probably a non-ATP-competitive 
inhibitor of hNek7, since our cavity analysis suggests it also occupies a region corresponding to the 
substrate-binding site (Figure 2). 
 
Figure 2. Representation of PKI complexed to PKAC-alpha and the relative position of 
GSK-3 Inhibitor XIII in the ATP and substrate-binding sites of hNek2. (A) Structural 
alignment between PKAC-alpha (PDB: 1FMO) (blue) and hNek2 (PDB: 2W5A) (green), 
both displayed in cartoon representation, with a root mean square deviation of 2.010 Å. 
The PKI peptide inhibitor is depicted in yellow whereas the GSK-3 Inhibitor XIII compound 
is shown in magenta alongside the ADP molecule (green) inside the ATP-binding site;  
(B) Detailed representation of the most favorable conformation adopted by GSK-3 
Inhibitor XIII (magenta) that could block the access to the substrate-binding site. 
In a recent review on approaches to discover non-ATP site kinase inhibitors by Gravin and Saiah 
(2012), Type III kinase inhibitors were described as small molecule inhibitors that bind in a pocket 
adjacent to the ATP site, such as the MEK inhibitor CI-1040, while Type V were described as a class 
of bivalent kinase inhibitors consisting ofa peptide analog to the substrate attached covalently to an 
ATP competitive small molecule [37]. Therefore, GSK-3 Inhibitor XIII has characteristics of a  
Type III, but also Type V kinase inhibitor, since it is a small molecule inhibitor that binds in a pocket 
that extends from the ATP to the substrate site. This is in agreement with the kinase assays performed 
for hNek7, particularly for hNek7 bound to GSK-3 Inhibitor XIII, where the percentage of 
phosphorylation activity did not increase with the decreasing inhibitor concentration relative to the 
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ATP concentration. In this case, a small concentration of the compound is sufficient to inhibit the 
kinase activity even if a relative higher amount of ATP is present, since the inhibitor is unlikely to 
compete with ATP for the same binding site in hNek7, but is most probably interfering with the 
peptide/substrate binding, contrary to hNek1 and 6 candidate inhibitors (Table 3). Moreover, our 
cavity analysis using KVFinder[38] suggests that there is a difference in the predicted binding regions of 
hNeks regarding their activation/phosphorylation status: the candidate compounds retrieved for the 
activation loop mutant hNeks occupy only the adenine and ribose-binding regions (Figure 1A”,B”) in 
contrast to the candidate compound retrieved for the wild-type hNek, which occupies mainly the 
phosphate groups-binding region extending to the substrate-binding site (Figure 1C”). 
Hence, from an initial set of 85 compounds, three were identified as promising inhibitors for  
hNeks 1, 6, and 7 (their 2D structures are depicted in Figure 3). Though, since these are commercial 
compounds also described to inhibit JNK, Cdk1/2, and GSK-3, further cell-based assays will be 
important to validate their activity and specificity towards hNeks. All these findings, particularly the 
one regarding the hNek7 candidate, which probably interferes with substrate binding, should be taken 
into account in order to design more potent and selective inhibitors for hNeks. 
 
Figure 3. Two dimensional structure of the best candidate compounds. (A) JNK Inhibitor II; 
(B) Isogranulatimide; (C) GSK-3 Inhibitor XIII. 
3. Materials and Methods 
3.1. Plasmid Constructions 
To express truncated hNek1 corresponding to its kinase domain only fused to a 6xHis tag, a  
specific primer set was used, 5'-CGGAATTCCATATGGAGAAGTATGTTAGACTAC-3' and  
5'-CGGGATCCTTAGCGTTTGGCTATAAAACCTTTCTC-3', to amplify the sequence from a  
full-length hNek1 cloned into pCMV5-FLAG kindly provided by Dr. Guido Lenz (Departamento de 
Biofísica, Instituto de Biociências, UFRGS, Porto Alegre, RS, Brazil). The resulting PCR-product was 
inserted into NdeI and BamHI restriction sites of the modified bacterial expression vector  
pET28a-TEV (Novagen/EMD Biosciences). Plasmids encoding hNek6 had previously been described by 
Meirelles et al. [39] and those encoding Nek7 were constructed in the same fashion. The orientation, 
frame, and sequence correctness of each DNA insert were confirmed by automated DNA sequencing. 
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3.2. Site-Directed Mutagenesis 
The hNek1 and hNek6 activation loop mutations T162A and S206A, respectively, were introduced 
by PCR-based mutagenesis according to Meirelles et al. [39]. Mutation was confirmed by DNA 
sequencing. The truncated activation loopmutant hNek2corresponding to its kinase domain only fused 
to a 6×His tag—hNek2(Δ272-445)-(T175A)—cloned into pET22b (Novagen) was kindly provided by 
Dr. Stefan Knapp (Section of Structural Biology, Institute of Cancer Research, Oxford, UK). The 
activation loop mutant constructs of hNek1, 2, and 6 lead to a higher protein expression and lower 
toxicity, and also to an increased stability in the case of hNek1 and 2, besides enabling to study the 
influence of their activation/phosphorylation status in the search and/or development of novel inhibitors. 
3.3. Protein Expression, Purification, and Dephosphorylation 
Soluble truncated mutant hNek1—hNek1(Δ262-1258)-(T162A)—fused to a 6xHis tag was 
expressed in BL21 (DE3/pRARE) cells at 18 °C using 1.0 mM isopropyl 1-thio-β-D-galactopyranoside 
(IPTG) for 4 h, in Terrific Broth medium. Soluble truncated mutant hNek2—hNek2(Δ272-445)-
(T175A) was expressed and purified according to Rellos et al. [27]. Soluble full-length wild-type 
hNek7—hNek7wt—fused to a 6xHis tag was expressed in E. coli BL21 (DE3/pRARE) or BL21 (DE3) 
cells. The cells were induced for 4 h using 1 mM of isopropyl-β-D-thio-galactoside (IPTG) at 28 °C. 
Induced cells were harvested and lysed by sonication in extraction buffer (50 mM HEPES pH 7.5;  
5 mM sodium phosphate, 300 mM NaCl, 5% glycerol) plus 1 mM PMSF and 625 µg/mL lysozyme. 
The cell lysates were separated by centrifugation at 16,000× g for 10 min at 4 °C in order to obtain the 
supernatant. Cleared fraction of 6xHis-hNek7 obtained by lysis was purified by affinity liquid 
chromatography using HiTrap Chelating affinity chromatography column (GE Healthcare) and eluted 
with an imidazole gradient (1 to 100 mM) in extraction buffer. Soluble full-length hNek6  
wild-type—6xHis-hNek6wt—and mutant—6xHis-hNek6(S206A)—or truncated hNek6 wild-type 
kinase domain—6xHis-hNek6(Δ1-44)—fused to a 6xHis tag were expressed and purified according to 
Meirelles et al. [39]. Dephosphorylated wild-type and mutant hNek6 were obtained according to 
Meirelles et al. [12]. 
3.4. Thermal Shift Assays 
Thermal shift assays were performed according to Meirelles et al. [12]. Proteins were buffered in  
10 mM HEPES pH 7.5, 150 mM NaCl and assayed at a final concentration of 2.0 µM in 25 µL volume 
in the presence of SYPRO-Orange (Molecular Probes, Eugene, OR, USA) at a dilution of 1 in 1000. 
OriginPro 8 software was used to fit data to the Boltzmann equation and Tm values were calculated by 
determination of the maximum of the first derivative. In the kinase inhibitor screen, the observed 
temperature shifts, ΔTm, for each inhibitor were recorded as the difference between the transition 
midpoints of sample and reference wells containing protein without inhibitor in the same plate. 
Observed temperature shifts above 4.0 °C were considered significant shifts, according to the work by 
Fedorov et al. [33]. 
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3.5. Kinase Assays 
Kinase assays were performed using LANCE®Ultra TR-FRET kinase assay protocol (PerkinElmer 
Life and Analytical Sciences, Shelton, CT, USA). IC50 values were determined by using a kinase 
concentration that phosphorylated 20%–50% of the ULight™-labeled p70S6K (Thr389) Peptide 
substrate (PerkinElmer Life and Analytical Sciences) at the ATP Km[apparent]. Kinase and ATP 
concentrations that matched these characteristics had been obtained in a previous assay, using a kinase 
concentration range between 2.5 nM and 640 nM, and an ATP concentration range between 0 and 25 µM. 
Inhibitor final concentration was 2×, 1× and 0.5× the ATP Km[apparent] concentration found for each 
kinase: 0.625 µM for hNek6(S206A) and hNek7wt, and 25 µM for hNek1(Δ262-1258)-(T162A). 
3.6. Homology Molecular Modeling 
Homology models for hNek1(Δ262-1258)-(T162A) and hNek6(S206A) were obtained based on the 
protein structure of hNek1 (PDB: 4APC) (unpublished) and hNek7 (PDB: 2WQN) [29], respectively, 
in which both the ATP and substrate sites were accessible, using YASARA (http://www.yasara.org). 
The alignment with the target sequence is improved using sequence-based profiles obtained from 
related Uniprot sequences (hNek1: Q96PY6-1; hNek6: Q9HC98-1; and hNek7: Q8TDX7-1) along 
with secondary structure prediction, to ensure high model quality. 
3.7. Molecular Docking 
Compounds showing the most significant ΔTm (ΔTm ≥ 4.0 °C) and increased inhibitory activity 
(percent phosphorylation ≤ 75%) were selected as best candidates and used as ligands for molecular 
docking against Neks. JNK Inhibitor II (ΔTm = 4.0 °C, percent phosphorylation = 71.5 ± 0.1) and 
Isogranulatimide (ΔTm = 6.5 °C, percent phosphorylation = 74.9 ± 10.4) were used considering 
hNek1(Δ262-1258)-(T162A) and hNek6(S206A) molecular models as targets, respectively. GSK-3 
Inhibitor XIII (ΔTm = 4.3 °C, percent phosphorylation = 46.3 ± 2.9) was used considering the hNek7 
crystal structure as the molecular target. Compound structures were obtained from the commercial 
SDF catalog (Calbiochem) and submitted to energetic parametrization and minimization on YASARA 
(http://www.yasara.org). Global molecular docking simulations were conducted using Autodock  
VINA [40] with 25 runs and 5 Å clustering RMSD. 
4. Conclusions 
We screened the activation loop mutant kinases hNek1 and hNek2, wild-type hNek7 and five 
hNek6 variants, with different activation/phosphorylation states, and compared them against 85 
compounds using thermal shift denaturation and identified one compound with significant Tm shift for 
hNek1(Δ262-1258)-(T162A), JNK Inhibitor II, and ten hit compounds for hNek7wt. Of these compounds, 
JNK Inhibitor II was validated by reducing hNek1(Δ262-1258)-(T162A) activity to 71.5% ± 0.1% at a 
50 µM concentration, while GSK-3 Inhibitor XIII was validated by reducing hNek7wt activity to 
46.3% ± 2.9%, at a 1.25 µM concentration. JNK Inhibitor II was also predicted to bind to the  
ATP-binding site of hNek1(Δ262-1258)-(T162A) as an ATP-competitive inhibitor, in contrast to  
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GSK-3 Inhibitor XIII, which showed a novel possible non-ATP-competitive inhibition of hNek7, but a 
most probable peptide/substrate-competitive inhibition. 
We also found that mutant hNek6, without the activation loop conserved phosphorylation, is a 
better target for inhibitor stabilization than an activated more phosphorylated hNek6 kinase. From this 
experiment, we retrieved one compound, Isogranulatimide, which produced a significant Tmshift for 
hNek6(S206A), but not for the other variants, which was later confirmed to reduce hNek6(S206A) 
activity to 74.9% ± 10.4% at 0.625 µM and to bind to its ATP-binding site. 
Further functional experiments in living cells are required to validate this findings, and structural 
studies with atomic resolution will be important to characterize the mechanistic association of 
hNek1(Δ262-1258)-(T162A), hNek6(S206A), and wild-type hNek7 with these promising compounds. 
Furhtermore, they may also function as scaffolds to design more potent and selective inhibitors for hNeks. 
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